Get unlimited access to Bruins cup coverage - Just 99¢

The Boston Globe

Business

Boston.com

Repligen completes Swedish acquisition

By Chris Reidy

 |  Globe Staff  

  December 20, 2011

Repligen Corp., a Waltham company that makes ingredients used in the manufacturing of biologic drugs, said it has completed the acquisition of the business of Novozymes Biopharma Sweden AB, the Swedish unit of Novozymes Biopharma. The all-cash transaction, which was announced in October, had Repligen making an upfront payment of 17 million euros, or $22.7 million. The transaction includes contingent milestone payments of 4 million euros, $5.2 million.

Stay with the story. Get full access to BostonGlobe.com for just 99¢

Unlimited access to BostonGlobe.com for only 99¢ for the first 4 weeks. You can cancel at any time.

  • The FULL story all day: Enjoy all of the high-quality, in-depth journalism in the print edition of the Boston Globe — plus breaking news that's updated 24/7.
  • A truly reader-friendly format: It's online news that looks and reads just like the newspaper — uncluttered, uninterrupted.
  • Breakthrough technology: The responsive design automatically adapts content so it always reads perfectly on the digital device of your choice.
Get started today

Free access for home delivery subscribers.

Just need to link your home delivery account; one easy step.

Link my home delivery account

BostonGlobe.comSubscriber Log In

Contact us for help

  • Phone

    888-MY-GLOBE

    Monday-Friday 6:00 a.m.- 5:00 p.m.

    Saturday, Sunday and Holidays 7:30 a.m.- 12:00 noon

  • Chat

    Start a chat

    Monday-Sunday 8:00 a.m.- 5:00 p.m.

  • E-mail

    support@bostonglobe.com